Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Acellular Tissue Engineered Vessel (ATEV) With That of an Autogenous Arteriovenous Fistula (AVF) in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

NCT05908084 is registered in ClinicalTrials.gov with Humacyte, Inc. as lead sponsor.

NCT NCT05908084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05908084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Acellular Tissue Engineered Vessel (ATEV) With That of an Autogenous Arteriovenous Fistula (AVF) in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Lead sponsor
Humacyte, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 7, 2023
Completion date
June 30, 2028
Enrollment
121 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease (esrd)